Try our beta test site

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Hoffmann-La Roche
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT02879981
First received: August 23, 2016
Last updated: March 8, 2017
Last verified: March 2017
  Purpose
This pilot, multicentric and observational study will assess the of safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants with acute bronchitis. Administration of treatment will be according to physician's recommendation under local labeling.

Condition Intervention
Bronchitis
Drug: Guaifenesin
Drug: Sulfamethoxazole
Drug: Trimethoprim

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Pediatric Patients With Acute Bronchitis

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of Participants With Related Adverse Events to Sulfamethoxazole + Trimethoprim + Guaifenesin as Assessed by Physician [ Time Frame: Baseline up to 5 Months ]

Secondary Outcome Measures:
  • Percentage of Participants With Compliance to Prescribed Dosage Regimen, As Assessed by Physician in Accordance With Local Clinical Practice and Local Labeling [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Change in Dose (Increase or Decrease) of Balsamic Bactrim [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Reason for Change in Dose (Increase or Decrease) of Balsamic Bactrim [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Change in Frequency of Balsamic Bactrim Dosing [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Predisposing Factors (Categories) for Safety (No specific predefined factors, these will be decided based on observations during study) [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Balsamic Bactrim Dose Interruptions [ Time Frame: Baseline up to 5 Months ]
  • Percentage of Participants With Balsamic Bactrim Dose Reintroduction [ Time Frame: Baseline up to 5 Months ]

Estimated Enrollment: 50
Actual Study Start Date: November 10, 2016
Estimated Study Completion Date: June 24, 2017
Estimated Primary Completion Date: June 24, 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pediatric Participants With Acute Bronchitis
Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim (sulfamethoxazole + trimethoprim + guaifenesin) according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to sulfamethoxazole + trimethoprim + guaifenesin as per the local label will be observed for safety.
Drug: Guaifenesin
Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Drug: Sulfamethoxazole
Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Drug: Trimethoprim
Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.

  Eligibility

Ages Eligible for Study:   4 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label
Criteria

Inclusion Criteria:

  • Participants starting treatment with Bactrim Balsamic suspension
  • Participants with a clinical diagnosis of acute bronchitis according to the pulmonologist clinical criteria

Exclusion Criteria:

  • Participants who have started treatment with another antibiotic at the time of the visit
  • Participants with no respiratory infections
  • Participants with mental disorders
  • Participants with severe hepatic parenchymal damage
  • Participants with severe renal failure making it difficult to monitor drug plasma concentration
  • Participants with hypersensitivity to any of Balsamic Bactrim active ingredients or excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02879981

Contacts
Contact: Reference Study ID Number: ML30017 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com

Locations
Peru
Hospital Emergencias Pediatricas; Unidad de Investigación Pediátrica Recruiting
La Victoria, Peru, 15033
Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional Recruiting
Lima, Peru, Lima 41
Clínica Anglo Americana-CENTRO DE INVESTIGACION PEDIATRIA CAA Recruiting
San Isidro, Peru, 27
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02879981     History of Changes
Other Study ID Numbers: ML30017
Study First Received: August 23, 2016
Last Updated: March 8, 2017

Additional relevant MeSH terms:
Bronchitis
Acute Disease
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Trimethoprim, Sulfamethoxazole Drug Combination
Sulfamethoxazole
Trimethoprim
Guaifenesin
Phenylpropanolamine
Chlorpheniramine, phenylpropanolamine drug combination
Anti-Infective Agents
Anti-Infective Agents, Urinary
Renal Agents
Anti-Bacterial Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Expectorants
Respiratory System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 24, 2017